NEW YORK, May 31, 2012 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), the company that operates the world's largest electronic marketplace for OTC-traded equities, today announced that Medicago Inc. (OTCQX: MDCGF; TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is now trading on the highest tier of the OTC market, OTCQX®.
(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO)
Medicago began trading today on the OTC market's prestigious tier, OTCQX International. Investors can find current financial disclosures and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
"The OTCQX platform supports a transparent marketplace with high quality issuers, financial information disclosure and efficient trading for U.S. investors," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome Medicago to OTCQX."
Dorsey & Whitney LLP will serve as Medicago's Principal American Liaison ("PAL") on OTCQX, responsible for providing guidance on OTCQX requirements and U.S. securities laws.
About Medicago Inc.
Medicago Inc. (OTCQX: MDCGF; TSX: MDG) trades in the United States on OTCQX under the symbol "MDCGF", and in Canada on the TSX Exchange under the symbol "MDG". Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The Company is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary VLP and manufacturing technologies. Medicago is a worldwide leader in the development of VLP vaccines using a transient expression system which produces recombinant vaccine antigens in plants. This technology has potential to offer more potent vaccines with speed and cost advantages over competitive technologies, enabling the development of a vaccine for testing in approximately one month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic, and supply large volumes of vaccine antigens to the world market. Medicago also intends to expand development into other areas such as biosimilars and biodefense products where the benefits of our technologies can make a significant difference. Additional information about Medicago is available at www.medicago.com.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest Open, Transparent and Connected marketplace platform, delivering price transparency in almost 10,000 OTC securities. Our OTC Link® trading system directly links broker-dealers that provide liquidity and execution services. We organize the wide spectrum of OTC-traded securities into three marketplaces to inform investors of opportunities and risks – OTCQX - The Intelligent Marketplace for the Best OTC Companies; OTCQB® - The Venture Marketplace; and OTC Pink® - The Open Marketplace. Our information-driven marketplace platform enables smarter trading through any broker at the best possible price, and empowers companies to build the best markets for their investors. To learn more about our Open, Transparent and Connected financial marketplaces, visit www.otcmarkets.com.
Subscribe to the OTCQX RSS Feed
SOURCE OTC Markets Group Inc.
Share this article